Hi everybody.
Thanks so much.
My name is Aaron Goldberg and a leukemia physician at Sloan-Kettering Cancer Center in New York City.
It's a pleasure to talk with you today about acute myeloid leukemia. And it's an updates from our European Hematology Association annual meeting.
So, in acute myeloid leukemia, this is a—it's a—it's a serious blood cancer. But outcomes have been getting better and better.
And in particular, I want to talk about work that we're presenting here at the European Hematology Association that involves health care resource utilization.
So again, as I mentioned, what we're able to show here is really the transformation of the paradigm of where care is delivered. So historically, it's been largely in the inpatient hospital setting, and now we're moving it really more towards the clinic.
So using the same retrospective cohort we looked at around the world, there's just so many different sites identified patients who were matched to receive, by their age and by the risk of their leukemia. And they received either the venetoclax regimens, plus azacitidine or decitabine, or a different regimen.
So for example, an intensive regimen or a non-intensive but non-venetoclax regimen. And what we found is that particularly when we compare those patients who received the high-intensity regimens, the patients who got the venetoclax-based regimens spent less time in the hospital.
And so they spent more time in the clinic going back and forth for lab appointments, but at least are not in the hospital. And then we're able to estimate how much does that cost, because obviously, if you're in the hospital, that costs a lot of money, and we're able to at least show that as a rough estimate, we're able to save money for the health care system by transforming the paradigm of care and moving it from the inpatient hospital to the outpatient setting.
So I think that we're in this real-world practice analysis able to show really the impact of the use of venetoclax in our acute myeloid leukemia patients. And so our outcomes are getting better and better. And we want them to get even better.
So thank you so much.